Synergy Pharma (SGYP) Tops Q2 EPS by 6c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St set to open higher as oil slips; telecoms hit by SpaceX spectrum deal
- Oil falls as Trump comments on Iran talks ease supply concerns
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
Get Alerts SGYP Hot Sheet
Join SI Premium – FREE
Synergy Pharma (NASDAQ: SGYP) reported Q2 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $5 million versus the consensus estimate of $4.53 million.
For earnings history and earnings-related data on Synergy Pharma (SGYP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Penguin Solutions (PENG) Tops Q4 EPS by 23c, Offers Guidance
- Neogen Corp. (NEOG) Tops Q1 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
